Results 21 to 30 of about 4,484 (145)

Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. [PDF]

PLoS ONE, 2016
BACKGROUND:Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries.
Guo-Feng Chen, Lai Wei, Jing Chen, Zhong-Ping Duan, Xiao-Guang Dou, Qing Xie, Wen-Hong Zhang, Lun-Gen Lu, Jian-Gao Fan, Jun Cheng, Gui-Qiang Wang, Hong Ren, Jiu-Ping Wang, Xing-Xiang Yang, Zhan-Sheng Jia, Qing-Chun Fu, Xiao-Jin Wang, Jia Shang, Yue-Xin Zhang, Ying Han, Ning Du, Qing Shao, Dong Ji, Fan Li, Bing Li, Jia-Liang Liu, Xiao-Xia Niu, Cheng Wang, Vanessa Wu, April Wong, Yu-Dong Wang, Jin-Lin Hou, Ji-Dong Jia, Hui Zhuang, George Lau   +34 more
doaj   +1 more source

Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational Study

Balkan Medical Journal, 2023
Background: Treatment using direct-acting antivirals provides high rates of sustained virologic response and a favorable safety profile for patients with chronic hepatitis C virus infection.
Ayşe Serra Artan, Şafak Mirioğlu, Zulal İstemihan, Elif Aksoy, Ahmet Burak Dirim, Bilger Çavuş, Özgür Akın Oto, Aslı Çifçibaşı-Örmeci, Fatih Beşışık, Yaşar Çalışkan, Savaş Öztürk, Halil Yazıcı, Sabahattin Kaymakoğlu, Aydın Türkmen   +13 more
doaj   +1 more source

Multivariate Chemometric Models and Application of Genetic Algorithm for Simultaneous Determination of Ledipasvir and Sofosbuvir in Pure Form and in Pharmaceutical Preparation; A Comparative Study [PDF]

Journal of Advanced Pharmacy Research, 2017
Objectives: Four multivariate chemometric methods have been developed for simultaneous determination of sofosbuvir and ledipasvir in their pure and pharmaceutical dosage forms.
Fathy Salama, Khalid Attia, Ahmed Abouserie, Ahmed El-Olemy, Ebrahim Abolmagd   +4 more
doaj   +1 more source

Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance

Viruses, 2015
Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries.
Bruno Roche, Audrey Coilly, Anne-Marie Roque-Afonso, Didier Samuel   +3 more
doaj   +1 more source

Real-Life Data on Sofosbuvir/Ledipasvir in Patients with Chronic Viral Hepatitis C Genotype 1b: A Single-Center Experience

The Turkish Journal of Gastroenterology, 2022
Background: The course of hepatitis C disease has changed with the use of direct-acting antiviral drugs in the treatment of the disease. The aim of this study was to evaluate the real-life efficacy and safety of the sofosbuvir/ledipasvir drug regimen in
Arif Mansur Coşar, Serdar Durak
doaj   +1 more source

Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years

Medicina
Background and Objectives: Chronic hepatitis C (CHC) can be cured with direct-acting antiviral (DAA) therapy. In Korea, sofosbuvir (SOF) and ledipasvir (LDV)/SOF were launched in 2016.
Yewan Park, Seong-Kyun Na, Jae-Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Gi-Ae Kim, Hyo-Young Lee, Young-Sun Lee, Jeong-Han Kim   +8 more
doaj   +1 more source

Comparison of Interferon‐Based and Interferon‐Free Treatments on the Prognosis of Hepatocellular Carcinoma After Hepatitis C Virus‐Sustained Virological Response: A Multicenter Study

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Aim We examine the impact of interferon (IFN)‐based and IFN‐free treatment on the prognosis of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) sustained virological response (SVR). Methods Clinical information was collected on 311 cases of HCC after HCV‐SVR from 16 facilities affiliated with the Kyushu Liver Surgery Study Group ...
Shinji Itoh, Norifumi Iseda, Tomoharu Yoshizumi, Takao Ide, Hirokazu Noshiro, Hisamune Sakai, Toru Hisaka, Masao Nakashima, Hiroaki Nagano, Hirohisa Okabe, Hiromitsu Hayashi, Atsushi Miyoshi, Kenji Kitahara, Yuko Takami, Atsushi Nanashima, Tamotsu Kuroki, Yuichi Endo, Kohji Okamoto, Masatoshi Kajiwara, Masahiko Sakoda, Toru Beppu, Mitsuhisa Takatsuki, Susumu Eguchi   +22 more
wiley   +1 more source

Should they wait? Two children under 3 years old infected by HCV 1b successfully treated by ledipasvir/sofosbuvir: A report of two cases

Liver Research, 2023
Although direct-acting antivirals (DAAs) have notably increased the sustained virological response (SVR) rates in hepatitis C virus (HCV)-infected adolescent patients, the efficacy and safety for young children under 3 years old remain unclear. Currently,
Mingna Li, Kuerbannisa Wulayin, Shutao Lin, Chao Wu, Lubiao Chen   +4 more
doaj   +1 more source

Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Viruses such as Ebola, Marburg, influenza, mpox, MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time‐consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost‐effective strategy to
Sola Akinbolade, Rhiannon Potter, Alex Inskip, Jane Nesworthy, Kirsti Brock, Gill Norman   +5 more
wiley   +1 more source

Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced

Gut and Liver, 2017
Background/AimsChronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia.Methods : Patients (n=30) were enrolled between September 2015 and April 2016.
Hyun Woong Lee, Ki Young Yoo, Joung Won Won, Hyung Joon Kim   +3 more
doaj   +1 more source